Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 7:05 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1849–1872 of 4,724 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Signs and Symptoms, Respiratory Clear all

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: 6-Thio-2'-Deoxyguanosine, Cemiplimab; Drug
Lead sponsor: Maia Biotechnology; Industry
Eligibility: 18 Years and older
Enrollment: 227 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: Birmingham, Alabama • Florham Park, New Jersey

Conditions: Malignant Pleural Effusion, Stage IV Metastatic Cancer, Lung Cancer
Interventions: Talimogene laherparepvec (TVEC), Nivolumab; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years to 99 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Hodgkin Disease, Lymphoma, Lymphoma, B-Cell, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Melanoma, Neoplasm Metastasis, Neoplasms, Head and Neck, Neoplasms, Squamous Cell, Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer Metastatic, Non-small Cell Carcinoma, Squamous Cell Cancer, Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Neoplasm, Lymphoma, Non-Hodgkin, Pancreatic Adenocarcinoma
Interventions: Intravenous (IV) SEA-CD40, Pembrolizumab, Subcutaneous (SC) SEA-CD40, Gemcitabine, Nab-paclitaxel; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 19
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 15 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: BGF; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years and older
Enrollment: 13,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Wilmington, Delaware

Conditions: Cystic Fibrosis, Depressive Symptoms, Chronic Obstructive Pulmonary Disease
Interventions: Bright Light Therapy (BLT) Lamp; Device
Lead sponsor: Erica Osborn; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania

Conditions: COPD, Self-management Behaviors
Interventions: Self-management barrier support, Basic COPD Education; Behavioral
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 40 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Hypoxia
Interventions: Supplemental oxygen via nasal cannula; Device
Lead sponsor: University of New Mexico; Other
Eligibility: 1 Day to 8 Years
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: Artesuante, Placebo capsules; Drug · Other
Lead sponsor: Joseph C. Wu; Other
Eligibility: 40 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Stanford, California

Conditions: Sleep-Disordered Breathing, Obstructive Sleep Apnea, Central Sleep Apnea, Chronic Pain, Opioid Use
Interventions: Acetazolamide, Placebo; Drug · Other
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: San Diego, California

Conditions: Telomere Disease
Interventions: Danazol; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 3 Years to 99 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Asthma in Children, Intellectual Disabilities (F70-F79), Developmental Disability, Autism Spectrum Disorder (ASD)
Interventions: Use of smart inhaler to enhance asthma inhaler proficiency; Behavioral
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: 10 Years to 17 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Long COVID, Chronic Fatigue Syndrome
Interventions: Transcutaneous vagus nerve stimulator; Device
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 21 Years to 70 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Tracheomalacia, Tracheobronchomalacia
Interventions: Not listed
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 21 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Osteoarthritic Knee Pain
Interventions: Wireless neuromodulation; Device
Lead sponsor: Curonix LLC; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 13
States / cities: Placentia, California • Denver, Colorado • Fort Lauderdale, Florida + 10 more

Conditions: Non-Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Ovarian Cancer
Interventions: PF-07257876; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 39
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Fayetteville, Arkansas + 25 more

Conditions: COPD, Smoking
Interventions: Cohort I, Cohort II; Other
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 206 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Sleep Disorders, Obstructive Sleep Apnea, Major Depressive Disorder, Dysthymic Disorder
Interventions: armodafinil, placebo; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 249 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 62
States / cities: Jasper, Alabama • Phoenix, Arizona • Tucson, Arizona + 50 more

Conditions: Chronic Bronchitis
Interventions: Faropenem medoxomil, placebo; Drug
Lead sponsor: Replidyne; Industry
Eligibility: 35 Years and older
Enrollment: 491 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: New Hope, Pennsylvania

Conditions: Spinal Cord Injury
Interventions: Manual and mechanical assisted cough, Incentive spirometry; Behavioral
Lead sponsor: Kessler Foundation; Other
Eligibility: 18 Years to 70 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: West Orange, New Jersey

Conditions: Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions: Afrezza Dose 1, Afrezza Dose 2; Combination Product
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 2
States / cities: Escondido, California • Walnut Creek, California

Conditions: Chronic Low-back Pain
Interventions: Integrative Breathwork Intervention; Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 70 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Stress Disorders, Post-Traumatic
Interventions: Mindfulness-based exercise; Behavioral
Lead sponsor: University of New Mexico; Other
Eligibility: 21 Years and older
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Neoplasms, Neoplasm Metastasis, Carcinoma, Non-Small-Cell Lung
Interventions: BI 891065, BI 754091; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 3
States / cities: Sarasota, Florida • Nashville, Tennessee • Milwaukee, Wisconsin

Conditions: Alpha 1-Antitrypsin Deficiency
Interventions: AAV8hAAT(AVL); Biological
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

THIO Sequenced With Cemiplimab in Advanced NSCLC

A Study of Nivolumab and Intrapleural Talimogene Laherparepvec for Malignant Pleural Effusion

Safety Study of SEA-CD40 in Cancer Patients

EXACERBATIONS AND REAL-WORLD OUTOMES INCLUDING CARDIOPULMONARY EVENTS AMONG PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (MITOS: EROS+CP US Study)

Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD

Comprehensive Self-management Support for COPD Patients

Apneic Oxygenation During Airway Management in Pediatric Patients

Dose-Escalation Study of Artesunate Patients With IPF

Managing Opioid Related Sleep Apnea With Acetazolamide

Low-Dose Danazol for the Treatment of Telomere Related Diseases

Using a Smart Inhaler to Support Asthma Management in Adolescents With Intellectual and Developmental Disabilities

tVNS in Long COVID-19

Tracheobronchomalacia: Treatment Outcomes

Freedom-1 Study for Chronic Knee Pain

Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors.

COPD Metabolome, Smoking Oxidants and Aberrant Ciliated Cell Function

Efficacy and Safety of Armodafinil for Adults With Excessive Sleepiness Obstructive Sleep Apnea/Hypopnea and Depression

A Trial to Evaluate the Efficacy and Safety of Faropenem Medoxomil In the Treatment of Chronic Bronchitis

Preventing Pneumonia and Other Respiratory Problems in Persons With Spinal Cord Injury

Afrezza® Dosing Optimization Study

Integrative Breathwork Intervention for Chronic Pain

Efficacy Study of Mindfulness-Based Exercise for Posttraumatic Stress Disorder (PTSD)

A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread

Gene Therapy for Alpha 1- Antitrypsin Deficiency